Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ADH1B | P00325 | 1/20 | 0.41 |
| ▸ | ADH1C | P00326 | 1/20 | 0.41 |
| ▸ | ADH1A | P07327 | 1/20 | 0.41 |
| ▸ | ADH4 | P08319 | 1/20 | 0.41 |
| ▸ | ADH7 | P40394 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14176594 | 0.97 | ADH1B (0.44) | HTTADH1BADH1CADH1AADH4 | |
| SCHEMBL104714 | 0.97 | ADH1B (0.44) | HTTADH1BADH1CADH1AADH4 | |
| SCHEMBL22899465 | 0.97 | ADH1B (0.44) | HTTADH1BADH1CADH1AADH4 | |
| SCHEMBL104968 | 0.94 | — | — | |
| SCHEMBL13884246 | 0.92 | SIGMAR1 (0.45) | HTTADH1BADH1CADH1AADH4 | |
| SCHEMBL104225 | 0.92 | — | — | |
| SCHEMBL17369631 | 0.92 | SIGMAR1 (0.45) | HTTADH1BADH1CADH1AADH4 | |
| Hydrochloric Acid SCHEMBL21879609 | 0.89 | — | — | |
| SCHEMBL21168663 | 0.82 | HTT (0.38) | HTTADH1BADH1CADH1AADH4 | |
| SCHEMBL15200275 | 0.82 | SIGMAR1 (0.40) | HTTSIGMAR1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| WO-2023168974-A1 | CHOLIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF AS TGR5 ALLOSTERIC AGONIST | 常州大学 | 2023-09-14 | — | — | WO | disclosed |
| US-20230183243-A1 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | VORONOIBIO INC. (KR) | 2023-06-15 | — | — | US | disclosed |
| US-20230183243-A1 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | VORONOIBIO INC. (KR) | 2023-06-15 | — | — | US | disclosed |
| US-20230150993-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-18 | — | — | US | disclosed |
| US-20220002242-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-01-06 | — | — | US | disclosed |
| US-11123079-B2 | Occlusive device with actuatable fixation members | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-10961189-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-03-30 | — | — | US | disclosed |
| WO-2019242689-A1 | CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF | 北京赛特明强医药科技有限公司 | 2019-12-26 | — | — | WO | disclosed |
| US-7939667-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-10 | — | — | US | disclosed |
| US-20110053920-A1 | SUBSTITUTED BICYCLIC PYRIMIDINES | CEPHALON, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-7879839-B2 | For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7585845-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-08 | — | — | US | disclosed |
| US-7585845-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-08 | — | — | US | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
| US-20070243166-A1 | Hepatitis C Inhibitor Compounds | LLINAS-BRUNET MONTSE | 2007-10-18 | — | — | US | disclosed |
| US-20070243166-A1 | Hepatitis C Inhibitor Compounds | LLINAS-BRUNET MONTSE | 2007-10-18 | — | — | US | disclosed |
| US-7238692-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053920-A1 | SUBSTITUTED BICYCLIC PYRIMIDINES | DPYD, P2RX5, P2RX7 | HTT 375/4885ADH1B 963/4885ADH1C 2097/4885 |
| US-20230183243-A1 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | TTK, TTBK1, TTBK2 | HTT 1004/4885ADH1B 2332/4885ADH1C 2151/4885 |
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | HTT 2474/4885ADH1B 4431/4885ADH1C 4366/4885 |
| US-10961189-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | HTT 1769/4885ADH1B 1975/4885ADH1C 2028/4885 |
| US-20230150993-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MKI67, MCL1, CCNI | HTT 1714/4885ADH1B 394/4885ADH1C 1659/4885 |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | HTT, HYPK, ATXN2 | HTT 1/4885ADH1B 3470/4885ADH1C 4278/4885 |
| US-20070243166-A1 | Hepatitis C Inhibitor Compounds | HAVCR2, CTRL, CTRC | HTT 4224/4885ADH1B 1251/4885ADH1C 312/4885 |
| US-20220002242-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | HTT 1769/4885ADH1B 1975/4885ADH1C 2028/4885 |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | CFD, TFPI, CFH | HTT 933/4885ADH1B 2577/4885ADH1C 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.